This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eiholzer, U. Articles by Simoni, M. Search for Related Content PubMed PubMed Citation Articles by Eiholzer, U. Articles by Simoni, M. Related Collections Neuroendocrinology and Pituitary Male Endocrinology

Hypothalamic and Gonadal Components of Hypogonadism in Boys with Prader-Labhart- Willi Syndrome

Institute Growth Puberty Adolescence (U.E., D.l., M.Sc.), CH-8006 Zurich, Switzerland; Department of Biostatistics, University of Zurich (V.R., T.G.), CH-8001 Zurich, Switzerland; Institute of Pediatric Endocrinology (J.G.), CH-4052 Basel, Switzerland; Department of Pediatric Endocrinology, Humboldt University (A.G.), D-13353 Berlin, Germany; and Institute of Reproductive Medicine, University of Muenster (M.Si.), D-48149 Muenster, Germany

Address all correspondence and requests for reprints to: Dr. Urs Eiholzer, Institute Growth Puberty Adolescence, Moehrlistrasse 69, CH-8006 Zurich, Switzerland. E-mail: mail{at}childgrowth.org.

Context: The specific form of hypogonadism in Prader-Labhart-Willi syndrome (PWS), central or peripheral, remains unexplained.

Objectives: The objectives of this study were to investigate the cause of hypogonadism in PWS and determine whether human chorionic gonadotropin (hCG) treatment can restore pubertal development.

Design: This was a clinical follow-up study, divided into two samples, over a duration of 1.5 and 4.5 yr.

Patients: Eight male infants and six peripubertal boys (age at start of observation, 0.06–0.93 and 8.1–10.8 yr, respectively) with genetically confirmed PWS were studied.

Intervention: hCG (500–1500 U twice weekly) was given from age 13.5 yr to the present.

Main Outcome Measures: Serum FSH, LH, inhibin B, and testosterone levels and pubertal development were the main outcome measures.

Results: Infants with PWS presented normal LH (2.3 ± 0.7 U/liter) and testosterone (2.5 ± 0.9 nmol/liter) levels (mean ± SEM at 5 months) compared with the reference range. However, two thirds of the boys displayed cryptorchidism. Inhibin B levels were at the lowest level of the normal range and decreased significantly between infancy and puberty (at 13 yr, 72 ± 17 pg/ml), whereas FSH secretion increased (9.9 ± 2.6 U/liter). Pubertal maturation stopped at an average bone age of 13.9 yr. hCG therapy increased testosterone (11 ± 2 nmol/liter) and reduced FSH (at 16 yr, 1.1 ± 0.9 U/liter) levels. Testicular volume (5.6 ± 1 ml) and inhibin B (26.5 ± 11.9 pg/ml) remained low.

Conclusion: Children with PWS display a specific form of combined hypothalamic (low LH) and peripheral (low inhibin B and high FSH) hypogonadism, suggesting a primary defect in Sertoli and/or germ cell maturation or an early germ cell loss. hCG therapy stimulates testosterone production and virilization.

This article has been cited by other articles:

				H. J. Hirsch, T. Eldar-Geva, F. Benarroch, O. Rubinstein, and V. Gross-Tsur Primary Testicular Dysfunction Is a Major Contributor to Abnormal Pubertal Development in Males with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2262 - 2268. [Abstract] [Full Text] [PDF]

				N. L.G. Miller, R. Wevrick, and P. L. Mellon Necdin, a Prader-Willi syndrome candidate gene, regulates gonadotropin-releasing hormone neurons during development Hum. Mol. Genet., January 15, 2009; 18(2): 248 - 260. [Abstract] [Full Text] [PDF]

				E. M Delemarre, B. Felius, and H. A Delemarre-van de Waal Inducing puberty Eur. J. Endocrinol., December 1, 2008; 159(suppl_1): S9 - S15. [Abstract] [Full Text] [PDF]

				A. P. Goldstone, A. J. Holland, B. P. Hauffa, A. C. Hokken-Koelega, M. Tauber, and on behalf of speakers contributors at the Second E Recommendations for the Diagnosis and Management of Prader-Willi Syndrome J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4183 - 4197. [Abstract] [Full Text] [PDF]